These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25625699)

  • 1. A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases.
    Carels N; Tilli T; Tuszynski JA
    PLoS One; 2015; 10(1):e0115054. PubMed ID: 25625699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
    Tilli TM; Carels N; Tuszynski JA; Pasdar M
    Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.
    Guest ST; Kratche ZR; Irish JC; Wilson RC; Haddad R; Gray JW; Garrett-Mayer E; Ethier SP
    Oncotarget; 2016 Jun; 7(24):36138-36153. PubMed ID: 27153554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Strategy Utilizing Protein-Protein Interaction Hubs for the Treatment of Cancer Diseases.
    Carels N; Sgariglia D; Junior MGV; Lima CR; Carneiro FRG; Silva GFD; Silva FABD; Scardini R; Tuszynski JA; Andrade CV; Monteiro AC; Martins MG; Silva TGD; Ferraz H; Finotelli PV; Balbino TA; Pinto JC
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
    Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
    Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets.
    Zaman N; Li L; Jaramillo ML; Sun Z; Tibiche C; Banville M; Collins C; Trifiro M; Paliouras M; Nantel A; O'Connor-McCourt M; Wang E
    Cell Rep; 2013 Oct; 5(1):216-23. PubMed ID: 24075989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population.
    Steiniger SC; Coppinger JA; Krüger JA; Yates J; Janda KD
    Stem Cells; 2008 Dec; 26(12):3037-46. PubMed ID: 18802034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients.
    Xu Y; Lin S; Zhao H; Wang J; Zhang C; Dong Q; Hu C; Desi S; Wang L; Xu Y
    Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31466383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-silico drug screening and potential target identification for hepatocellular carcinoma using Support Vector Machines based on drug screening result.
    Yang WL; Lee YE; Chen MH; Chao KM; Huang CY
    Gene; 2013 Apr; 518(1):201-8. PubMed ID: 23220021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
    Bordinhão AL; Evangelista AF; Oliveira RJ; Macedo T; Silveira HC; Reis RM; Marques MM
    Oncol Rep; 2016 Dec; 36(6):3197-3206. PubMed ID: 27748845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening of chemical compounds active against breast cancer cell lines based on cell cycle modelling, prediction of cytotoxicity and interaction with targets.
    Konova V; Lagunin A; Pogodin P; Kolotova E; Shtil A; Poroikov V
    SAR QSAR Environ Res; 2015; 26(7-9):595-604. PubMed ID: 26358808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
    Yakisich JS; Venkatadri R; Azad N; Iyer AKV
    J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
    Pal R; Berlow N
    Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
    Lee H; Kang S; Kim W
    PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.
    Chen J; Xu J; Li Y; Zhang J; Chen H; Lu J; Wang Z; Zhao X; Xu K; Li Y; Li X; Zhang Y
    Oncotarget; 2017 Feb; 8(6):10171-10184. PubMed ID: 28052038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.